Canadian Cancer Trials Group Bulletins


Recent Publications

There were two recent publications both reporting primary results -- Canadian Cancer Trials Group MAP.3 and Canadian Cancer Trials Group IND.188.

Canadian Cancer Trials Group MAP.3
A Phase III Randomized Study of Exemestane versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer

Goss PE, Ingle JN, AlÚs-Martinez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, McTiernan A, Robbins J, Johnson KC, Martin LW, Winquist E, Sarto GE, Garber JE, Fabian CJ, Pujol P, Maunsell E, Farmer P, Gelmon KA, Tu D, Richardson H. Exemestane for Breast-Cancer Prevention in Postmenopausal Women (ONLINE). N Engl J Med, 2011.

Canadian Cancer Trials Group IND.188
A Clinical and Pharmacokinetic Study of Sb939 in Patients with Advanced Cancer

Razak ARA, Hotte SJ, Siu LL, Chen EX, Hirte HW, Powers J, Walsh W, Stayner LA, Laughlin A, Novotny-Diermayr V, Zhu J, Eisenhauer EA. Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours. Br J Cancer 104: 756-62, 2011.